AURORA CANNABIS (ACB) Company Report

Aurora Cannabis Inc.'s wholly owned subsidiary, MedReleaf Australia, has entered into a distribution partnership with Leafio, the wholesale distribution arm of Montu Australia.
This strategic partnership aims to expand patient access to medical cannabis across Australia and support healthcare professionals with educational resources.
Leafio will serve as a wholesaler for Aurora's medical cannabis products, including MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., and IndiMed brands, distributing them through its nationwide supply chain that services over 4,000 pharmacies.

5 days ago

Press Release

Rubicon Organics Appoints Glen Ibbott as CFO

ACB

CFO Change

Management Change

Hiring

Rubicon Organics Inc. announced the appointment of Glen Ibbott as its Chief Financial Officer and Corporate Secretary on November 12, 2025.
Mr. Ibbott previously served as CFO at Aurora Cannabis from 2017 to 2024, where he played a pivotal role in the company's rapid growth and international expansion.
He has been working as an interim CFO with Rubicon Organics for the past six months and brings over 25 years of leadership experience in publicly-traded life sciences and cannabis companies.

Nov 13, 2025, 1:00 AM

Press Release

Aurora Cannabis Reports Fiscal Q2 2026 Results

ACB

Earnings

Guidance Update

Revenue Acceleration/Inflection

Aurora Cannabis reported fiscal Q2 2026 net revenue of $90 million, an 11% increase year-over-year, driven by 15% growth in global medical cannabis revenue and 22% growth in international revenue.
Adjusted EBITDA for Q2 2026 rose more than 52% to $15 million, while consolidated adjusted gross margin improved 700 basis points to 61%.
The company ended the quarter with $142 million in cash and cash equivalents and no cannabis business debt as of September 30, 2025.
For fiscal Q3 2026, Aurora Cannabis anticipates year-over-year consolidated net revenue growth, primarily from 8-12% growth in its global medical cannabis segment, and expects to achieve positive free cash flow.

Nov 5, 2025, 1:00 PM

Transcript

Aurora Cannabis Announces Fiscal Q2 2026 Results

ACB

Earnings

Guidance Update

Revenue Acceleration/Inflection

Aurora Cannabis reported Global Medical Cannabis Net Revenue of $70.5 million, a 15% year-over-year increase, and International Medical Cannabis Net Revenue grew 22% to $42.7 million for the second quarter of fiscal 2026, ended September 30, 2025.
Adjusted EBITDA for the quarter increased 52% year-over-year, reaching $15.4 million.
The company recorded a net loss from continuing operations of $53.2 million for Q2 2026, compared to a net income of $1.4 million in the prior year period, while Adjusted net income was $7.1 million.
For Q3 2026, Aurora Cannabis expects consolidated net revenue to increase year-over-year, driven primarily by 8% to 12% growth in its Global Medical Cannabis segment, and anticipates positive free cash flow.

Nov 5, 2025, 12:25 PM

6-K

Aurora Cannabis Reports Increased Net Loss in Q2 2026 Amid Impairment Charges and Higher Medical Cannabis Revenue

ACB

Earnings

Financial Restatement

Debt Issuance

Aurora Cannabis Inc. reported a net loss of $(53,049) thousand for the three months ended September 30, 2025, primarily due to a $(31,901) thousand impairment of intangible assets and goodwill.
Net revenue increased to $90,366 thousand for the three months ended September 30, 2025, up from $81,122 thousand in the prior year, driven by a $9.2 million increase in total medical cannabis net revenue, particularly from international markets.
The company experienced a free cash flow outflow of $(42,274) thousand for the three months ended September 30, 2025, a significant decrease of $51.5 million from the previous quarter, largely due to a $36.4 million working capital investment.
As of September 30, 2025, the subsidiary Bevo was not in compliance with its fixed charge coverage ratio financial covenant and non-financial covenant to provide audited financial statements under its credit agreement.

Nov 5, 2025, 12:16 PM

6-K

Aurora Cannabis Announces Fiscal Q2 2026 Results

ACB

Earnings

Guidance Update

Revenue Acceleration/Inflection

For the second quarter of fiscal 2026, ending September 30, 2025, Aurora Cannabis reported record global medical cannabis net revenue of $70.5 million, a 15% year-over-year increase, and record international medical cannabis net revenue of $42.7 million, up 22%.
The company achieved Adjusted EBITDA of $15.4 million, representing a 52% growth compared to the prior year period, with total net revenue increasing 11% year-over-year to $90.4 million.
Aurora maintains a strong balance sheet with $141.9 million of cash and expects positive free cash flow in Q3 2026, driven by an anticipated 8% to 12% growth in its Global Medical Cannabis segment.

Nov 5, 2025, 12:00 PM

Press Release

Aurora Cannabis Announces Investment in German Manufacturing Facility

ACB

New Projects/Investments

Aurora Cannabis Inc. announced a five-year investment in operational upgrades for its EU-GMP manufacturing facility in Leuna, Germany, as of September 18, 2025.
These upgrades are designed to increase flower growth capacity, enhance product quality, and improve cost efficiency.
The investment aims to strengthen the company's supply chain resilience and expand its domestic EU-GMP certified manufacturing capabilities to meet the growing demand for high-quality medical cannabis in Europe.
The Leuna facility, which is one of only three licensed cultivation sites in Germany, will also gain the ability to grow additional cannabis cultivars from Aurora's genetics library.

Sep 18, 2025, 12:54 PM

6-K

Aurora Cannabis Announces Investment in German Manufacturing Facility

ACB

New Projects/Investments

Aurora Cannabis Inc. is making a five-year investment into operational upgrades at its EU-GMP manufacturing facility in Leuna, Germany, as announced on September 18, 2025.
This investment aims to increase flower growth capacity, enhance product quality, and drive cost efficiency at the facility.
The upgrades are expected to strengthen the supply chain, expand domestic EU-GMP certified manufacturing capabilities, and position the company to meet the growing demand for high-quality medical cannabis in Europe.
Aurora Leuna, one of only three licensed cultivation facilities in Germany, will also gain the ability to grow additional cultivars from Aurora's leading genetics library.